DCK confers sensitivity of DCTD-positive cancer cells to oxidized methylcytidines
Accepted date: 24 May 2022
Published date: 15 Jul 2023
Copyright
Ya-Hui Zhao , Wei Jiang , Hai Gao , Guo-Zheng Pang , Yu-Shuang Wu , Yuan-Xian Wang , Meng-Yao Sheng , Jia-Ying Xie , Wan-Ling Wu , Zhi-Jian Ji , Ya-Rui Du , Lei Zhang , Xiao-Qin Wang , Colum P. Walsh , Hai Jiang , Guo-Liang Xu , Dan Zhou . DCK confers sensitivity of DCTD-positive cancer cells to oxidized methylcytidines[J]. Protein & Cell, 2023 , 14(7) : 532 -537 . DOI: 10.1093/procel/pwac028
| 1 |
Appelbaum FR, Rowe JM, Radich J, et al. Acute myeloid leukemia. N Engl J Med 1999;341:1051–1062.
|
| 2 |
Bruno PM, Liu Y, Park GY, et al. A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress. Nat Med 2017;23:461–471.
|
| 3 |
Ebrahem Q, Mahfouz RZ, Ng KP, et al. High cytidine deaminase expression in the liver provides sanctuary for cancer cells from decitabine treatment effects. Oncotarget 2012;3:1137–1145.
|
| 4 |
Fugger K, Bajrami I, Dos Santos MS, et al. Targeting the nucleotide salvage factor DNPH1 sensitizes BRCA-deficient cells to PARP inhibitors. Science 2021;372:156–165.
|
| 5 |
Jamieson GP, Finch LR, Snook M, et al. Degradation of 1-beta-D-arabinofuranosylcytosine 5′-triphosphate in human leukemic myeloblasts and lymphoblasts. Cancer Res 1987;47:3130–3135.
|
| 6 |
Jiang H, Pritchard JR, Williams RT, et al. A mammalian functional- genetic approach to characterizing cancer therapeutics. Nat Chem Biol 2011;7:92–100.
|
| 7 |
Lin YW, Slape C, Zhang Z, et al. NUP98-HOXD13 transgenic mice develop a highly penetrant, severe myelodysplastic syndrome that progresses to acute leukemia. Blood 2005;106:287–295.
|
| 8 |
Maley GF, Maley F. The significance of the substrate specificity of T2r+-induced deoxycytidylate deaminase. J Biol Chem 1966;241:2176–2177.
|
| 9 |
Saba HI. Decitabine in the treatment of myelodysplastic syndromes. Ther Clin Risk Manag 2007;3:807–817.
|
| 10 |
Scarano E. The enzymatic deamination of 6-aminopyrimidine deoxyribonucleotides. I. The enzymatic deamination of deoxycytidine 5′-phosphate and of 5-methyldeoxycytidine 5- methyldeoxycytidine 5′-phosphate. J Biol Chem 1960a;235:706–713.
|
| 11 |
Scarano E. The enzymatic deamination of 6-aminopyrimidine deoxyribonucleotides. II. Purification and properties of a 6-aminopyrimidine deoxyribonucleoside 5′-phosphate deaminase from unfertilized eggs of sea urchine. J Biol Chem 1960b;235:706–713.
|
| 12 |
Vilpo JA, Vilpo LM. Nucleoside monophosphate kinase may be the key enzyme preventing salvage of DNA 5-methylcytosine. Mutat Res-Fund Mol M 1993;286:217–220.
|
| 13 |
Wang L, Gural A, Sun XJ, et al. The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation. Science 2011;333:765–769.
|
| 14 |
Wang T, Yu H, Hughes NW, et al. Gene essentiality profiling reveals gene networks and synthetic lethal interactions with oncogenic ras. Cell 2017;168:890–903.e15e815.
|
| 15 |
Zauri M, Berridge G, Thézénas ML, et al. CDA directs metabolism of epigenetic nucleosides revealing a therapeutic window in cancer. Nature 2015;524:114–118.
|
/
| 〈 |
|
〉 |